AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T14:49:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
Tue 13 May 25, 01:15 PMBioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025
Wed 07 May 25, 01:15 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -14.24198M | -8.97938M | -10.41770M | -18.49477M | -44.30329M |
| Minority interest | - | - | - | - | - |
| Net income | -14.24198M | -8.97938M | -10.41770M | -18.01551M | -29.93860M |
| Selling general administrative | 5.89M | 6.58M | 11.33M | 15.58M | 25.61M |
| Selling and marketing expenses | - | 0.17M | 0.17M | - | 0.01M |
| Gross profit | 0.34M | 0.37M | 0.15M | 0.12M | 0.05M |
| Reconciled depreciation | 0.21M | 0.19M | 0.15M | 0.12M | 0.09M |
| Ebit | -15.64713M | -11.55519M | -15.13744M | -18.97403M | -26.30787M |
| Ebitda | -15.43715M | -11.36614M | -14.97171M | -18.99296M | -42.39882M |
| Depreciation and amortization | 0.21M | 0.19M | 0.17M | -0.01894M | -16.09095M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -15.64713M | -11.55519M | -15.22077M | -18.97403M | -26.30787M |
| Other operating expenses | 16.01M | 11.96M | 15.37M | 18.98M | 26.35M |
| Interest expense | - | - | - | 0.01M | 1.82M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.27M | 0.62M | 0.55M | - | - |
| Net interest income | 0.27M | 0.62M | 0.29M | 0.01M | -1.81537M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | -0.00001M | -0.47926M | -14.36469M |
| Total revenue | 0.36M | 0.40M | 0.15M | 0.12M | 0.05M |
| Total operating expenses | 15.98M | 11.93M | 15.37M | 18.98M | 26.35M |
| Cost of revenue | 0.02M | 0.03M | 0.17M | - | - |
| Total other income expense net | 1.41M | 2.58M | 4.80M | 0.48M | -17.99542M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -14.24198M | -8.97938M | -15.93782M | -18.49477M | -44.30329M |
| Net income applicable to common shares | - | - | - | -18.49477M | -44.30329M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 4.08M | 12.28M | 12.61M | 16.43M | 22.45M |
| Intangible assets | 0.53M | 0.62M | 0.71M | 0.80M | 0.59M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.17M | 0.22M | 0.31M | 0.36M | 0.44M |
| Total liab | 3.72M | 3.75M | 1.06M | 0.60M | 0.86M |
| Total stockholder equity | 0.36M | 8.53M | 11.55M | 15.83M | 21.60M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 2.38M | 3.27M | 0.71M | 0.13M | 0.13M |
| Common stock | 0.00089M | 0.00069M | 0.00047M | 0.00037M | 0.00035M |
| Capital stock | 0.01M | 0.01M | - | 0.02M | 0.02M |
| Retained earnings | -169.92069M | -155.67872M | -167.05638M | -152.64090M | -134.14613M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 1.51M | 0.55M | 0.88M | 1.68M | 21.03M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3.72M | 3.75M | 1.06M | 0.44M | 0.36M |
| Current deferred revenue | - | - | 0.00000M | - | - |
| Net debt | -1.51119M | -0.54789M | -0.72206M | -1.37493M | -20.35603M |
| Short term debt | - | 0.32M | 0.16M | 0.14M | 0.18M |
| Short long term debt | - | - | - | - | 0.06M |
| Short long term debt total | - | 0.16M | 0.16M | 0.30M | 0.67M |
| Other stockholder equity | 170.26M | 164.20M | 178.59M | 168.46M | 155.73M |
| Property plant equipment | - | - | - | 0.50M | 0.40M |
| Total current assets | 3.14M | 11.14M | 11.39M | 15.13M | 21.47M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 15.01M | 20.99M |
| Short term investments | 1.44M | 10.18M | 10.18M | 13.07M | - |
| Net receivables | 0.02M | 0.19M | 0.02M | 0.02M | 0.00500M |
| Long term debt | - | - | - | - | 0.19M |
| Inventory | - | - | 0.00000M | - | - |
| Accounts payable | 1.34M | 0.48M | 0.19M | 0.17M | 0.05M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | 0.00000M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.05M | 0.15M | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.94M | 1.14M | 1.22M | 1.31M | 0.99M |
| Capital lease obligations | - | 0.00000M | - | 0.30M | 0.42M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 9.01M | 0.51M | -0.17181M | -13.47939M | -0.03066M |
| Change to liabilities | - | - | - | 0.12M | -0.06802M |
| Total cashflows from investing activities | 8.90M | 0.51M | 3.25M | -13.47939M | -0.03066M |
| Net borrowings | - | - | - | - | 0.25M |
| Total cash from financing activities | 2.85M | 7.38M | 2.35M | 0.00000M | 21.32M |
| Change to operating activities | - | - | - | -0.09493M | 0.38M |
| Net income | -14.24198M | -8.97938M | -10.41770M | -18.49477M | -44.30329M |
| Change in cash | 0.96M | -0.33649M | -0.82939M | -19.35015M | 17.96M |
| Begin period cash flow | 0.55M | 0.88M | 1.71M | 21.03M | 3.06M |
| End period cash flow | 1.51M | 0.55M | 0.88M | 1.68M | 21.03M |
| Total cash from operating activities | -10.78896M | -8.23035M | -6.43021M | -5.87076M | -3.32991M |
| Issuance of capital stock | 3.10M | 0.00000M | 2.27M | 0.00000M | 21.07M |
| Depreciation | 0.21M | 0.19M | 0.17M | 0.12M | 0.09M |
| Other cashflows from investing activities | -0.11607M | -0.10619M | - | - | - |
| Dividends paid | 0.27M | 0.62M | 0.57M | - | - |
| Change to inventory | - | - | -0.00000M | - | - |
| Change to account receivables | 0.17M | -0.16910M | -0.00330M | -0.01100M | 0.01M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 0.17M | 7.38M | 2.35M | -13.47939M | 0.25M |
| Change to netincome | - | - | - | 12.49M | 39.43M |
| Capital expenditures | 0.12M | 0.11M | 0.17M | 0.44M | 0.03M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 1.31M | 0.03M | 0.52M | 0.01M | 0.32M |
| Stock based compensation | 3.33M | 2.81M | 7.78M | 12.61M | 23.11M |
| Other non cash items | -1.39207M | -2.28124M | -4.47654M | -0.12354M | 1.27M |
| Free cash flow | -10.90503M | -8.33653M | -6.60125M | -6.31098M | -3.36057M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BRTX BioRestorative Therapies Inc |
-0.013 3.18% | 0.40 | - | - | 16.86 | 19.18 | 1.05 | 0.13 |
| NVO Novo Nordisk A/S |
1.15 2.51% | 47.03 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 45.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
1.41 0.30% | 468.20 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.50 1.06% | 619.00 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
40 Marcus Drive, Melville, NY, United States, 11747
| Name | Title | Year Born |
|---|---|---|
| Mr. Lance Alstodt | Chairman, Pres & CEO | 1971 |
| Mr. Francisco J. Silva | Chief Scientist, VP of R&D, Sec. and Director | 1975 |
| Mr. Robert Eugene Kristal | Chief Financial Officer | 1968 |
| Mr. Robert Paccasassi | VP of Quality Assurance & Regulatory Compliance | 1969 |
| Dr. Wayne J. Olan M.D. | Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board | NA |
| Mr. Lance Alstodt | Chairman of the Board, President & CEO | 1971 |
| Mr. Francisco J. Silva | Chief Scientist, VP of Research & Development, Secretary and Director | 1975 |
| Mr. Robert Paccasassi | Vice President of Quality Assurance & Regulatory Compliance | 1969 |
| Mr. Francisco J. Silva | VP of Research & Development, Secretary and Director | 1975 |
| Ms. Crystal Romano | Head of Global Commercial Operations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...